Re: The Neurobiology, Neuropharmacology, and Phar ma cologic Treat ment of Paraphilias and Com pul sive Sex ual Be hav iour Dear Ed i tor:
Dr Brad ford re cently re viewed the pharma co logic treat ment of the paraphilias and com pul sive sex ual be hav iour (1) . As a rec og nized ex pert in fo ren sic psychi a try and an opin ion leader he is poten tially an im por tant agent in chang ing phy si cian prac tices and pa tient outcomes (2) . There fore, we be lieve it is im per a tive that Dr Brad ford's rec ommen da tions be based on the best available em pir i cal ev i dence, if they are to do more good than harm.
To sup port his al go rithm for the treatment of paraphilias Dr Brad ford reviewed se lected clin i cal stud ies, briefly de scrib ing some of them (1) . There is a rel a tively high risk that nar ra tive reviews of this type will be ten u ous, incom plete, or, worse still, based on bi ased study se lec tion and ci ta tion. As well, they may ad vo cate ther apy even after it has been shown to be use less or harm ful (3) (4) (5) (6) .
To al low cli ni cians to em ploy them confi dently treat ment rec om men da tions should, when ever pos si ble, be based on 3 el e ments: em pir i cal ev i dence from a sys tem atic re view, an ex am i na tion of the ev i dence's strength, and ex plicit spec i fi ca tion of val ues or pref er ences asso ci ated with out comes (7) . Dr Bradford's re view ful filled none of these meth od olog i cal re quire ments.
Cli ni cian con fi dence in Dr Brad ford's rec om men da tions must be un der mined by the fact that his re view does not include the meth od olog i cally ro bust metaanalysis by White and oth ers (8) . The ob jec tive of this metaanalysis was to de ter mine the ef fec tive ness of ther apies to as sist peo ple who have sex ual pref er ence dis or ders and those who have been con victed of sex ual of fences. A com pre hen sive search of the world lit era ture in Au gust 1998 iden ti fied only a sin gle ran dom ized con trolled trial of antilibidinal med i ca tion that met method olog i cal cri te ria in tended to min i mize bias. This trial found that medroxyprogesterone (MPA) to gether with imaginal de sen si ti za tion was no better than imaginal de sen si ti za tion alone for prob lem atic or anom a lous sexual be hav iour and de sire (9) .Yet, Dr Brad ford did not cite this trial or any orig i nal study pub lished af ter 1998.
White and col leagues re ported, "At pres ent there are so few data to ei ther sup port or re fute the use of antilibidinal drugs, such as medroxyprogesterone, that it is dif fi cult to jus tify their use outside of a well-con ducted trial." This state ment con trasts with Dr Brad ford's sug ges tion that "clin i cal stud ies show that MPA has a sig nif i cant im pact on devi ant sex ual fan ta sies and de vi ant sex ual urges and be hav iour."
Cli ni cians are left with less con fi dence in Dr Brad ford's rec om men da tions than might have been the case had they been de rived from a re view pro cess that was less prone to bias. We think cli ni cians should use antilibidinal drug treat ments with cau tion.
Sex of fend ers are of ten un der in tense pres sure to com ply with clin i cal treatment rec om men da tions, re gard less of the weight of ev i dence (or lack thereof) sup port ing the rec om mended treat ment. As such, we be lieve re search ers must be meth od olog i cally rig or ous in study ing their treat ment. Cli ni cians carry a heavy eth i cal re spon si bil ity to eval u ate carefully the ev i dence sup port ing any treatment they rec om mend to these pa tients. False con fi dence in treat ments for sex of fend ers can re sult in harm, not only to the pa tients but also to those whom we would most wish to pro tect. 
Open-Label Risperidone Treatment of 6 Children and Adolescents With Autism
Dear Ed i tor:
Au tis tic dis or der is a per va sive de vel opmen tal dis or der char ac ter ized by impaired re cip ro cal so cial in ter ac tion, com mu ni ca tion skills, and imag i na tive ac tiv ity. No ef fec tive phar ma co logic strat e gies have been de vel oped for treatment of its core symp toms. Nev er theless, pharmacotherapy is an im por tant treat ment mo dal ity and of ten part of a com pre hen sive ther a peu tic pro gram.
An im bal ance in the serotonergic neu rotrans mit ter sys tem may un der lie as pects of the pa thol ogy ob served in au tis tic patients (1). Risperidone, an atyp i cal antipsychotic that is both a se ro to nin and do pa mine an tag o nist, has been shown to treat adults with au tism ef fec tively (2) . Studies have shown that risperidone also im proves symp toms in sev eral psy chi atric dis or ders of older chil dren and ad oles cents (3) (4) (5) . In this let ter, we de scribe its use for treat ing chil dren with au tism. Our sam ple con sisted of 9 sub jects with a DSM-IV di ag no sis of au tis tic dis or der (7 males and 2 fe males; me dian age 7.1 yrs, range 3.4 to 13.4 yrs). Screening pro ce dures in cluded med i cal his tory, phys i cal and neu ro log i cal ex am i na tions, com plete blood count, elec tro lytes, glucose, se rum urea ni tro gen, creatinine, liver func tion, uri nal y sis, ECG, EEG, and au di tory evoked po ten tials. Pa tients were drug-free for at least 4 weeks before the be gin ning of the trial. No other psy cho ac tive med i ca tion was given during the study.
The sub jects un der went a 12-month trial. Risperidone was started at 0.5 mg daily and ti trated up ward to a max i mum of 3 mg daily.
Be hav ioural rat ings were car ried out at base line and at fixed in ter vals (3, 6 , and 12 months). The fol low ing in stru ments were em ployed: Clin i cal Global Im pression (CGI) (6), Be hav ioural Sum marized Eval u a tion Scale (BSE) (7) , and Vineland So cial Ma tu rity Scale (VSMS) (8) .
Most of the screen ing tests, in clud ing com plete blood count, liver func tion, elec tro lytes, glu cose, se rum urea ni trogen, creatinine, uri nal y sis, and EEG, were also per formed 3 times dur ing the study (at 3, 6, and 12 months). Blood pres sure was mon i tored dur ing the first days of the trial. Side ef fects were eval uated us ing the Extrapyramidal Symptoms Rat ing Scale (ESRS) (9) .
Three pa tients were with drawn from the study due to fam ily non com pli ance, and 6 sub jects com pleted the whole trial.
All par ents re ported some be hav ioural im prove ment, such as in creased awareness and so cial in ter ac tion, as well as decreased self-abuse, ir ri ta bil ity, hy per ac tiv ity, and sleep dis tur bance.
Five of the 6 risperidone-treated pa tients were cat e go rized as re spond ers on the ba sis of the CGI Scale. The Wilcoxon signed-rank test showed that the decrease in the to tal BSE score be tween base line and month 12 was sta tis ti cally sig nif i cant (P = 0.03). No sig nif i cant changes were noted us ing the VSMS.
Un to ward ef fects in cluded mild se dation (2 cases) and weight gain (1 case). One of the pa tients ex pe ri enced an ep ilep tic sei zure 6 months af ter start ing risperidone ther apy. Liver func tion tests, EEG, and other lab o ra tory stud ies re mained within nor mal lim its. Blood pres sure did not vary from nor mal val ues.
Our study showed that risperidone was able to re duce self-abuse, ag gres sion, and hy per ac tiv ity in au tis tic chil dren. The ob vi ous fac tors ham per ing its gener al iza tion in clude the small num ber of pa tients, the unblind na ture, and the lack of con trol groups. Con trolled re search is needed to fur ther eval u ate the ef fi cacy of risperidone in treat ing au tism.
Fabiana Vercellino, MD Elisabetta Zanotto, MD Giambattista Ravera, MD Edvige Veneselli, MD Genoa, Italy
Bupropion and Drug-Induced Parkinsonism
I re port the case of a 48-year-old male phy si cian who pre sented with a ma jor de pres sive ep i sode (MDE). He had suffered with sea sonal af fec tive dis or der (SAD) for sev eral years. He de scribed him self as al ways hav ing been ob sessional and perfectionistic.
Ini tially, he had re sponded pos i tively to citalopram at a dos age of 20 mg daily, although he had ex pe ri enced sig nif i cant sex ual side ef fects and a with drawal syndrome when he dis con tin ued it. There is a pos i tive fam ily his tory of de pres sive ill ness in his mother postmenopause, requir ing hos pi tal iza tion and re spon sive to med i ca tion man age ment. His 18-year-old son also pre sented with depres sive ill ness at the same time as the fa ther and ini tially re sponded pos i tively to bupropion (Wellbutrin).
Ma jor de pres sion was ev i dent in clin i cal in ter view, with self-re port, Beck Depres sion In ven tory (BDI), and the Hospi tal Anx i ety and De pres sion and (HAD) Scale show ing mod er ately severe de pres sion with as so ci ated anx i ety. The pa tient was tak ing beta blockers for es sen tial hy per ten sion, which was well con trolled. He had self-med i cated with nefazodone at doses up to 200 mg daily, with lit tle ev i dent ben e fit apart from improved sleep pat tern. When he was next as sessed, the de pres sive af fect was more sig nif i cant. Bupropion SR was added at a dos age of 150 mg daily, with some clonazepam as needed for break through panic. Clin i cal im prove ment in
